Study of Microwave Thermosphere Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm

Sponsor
Tianjin Third Central Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05361538
Collaborator
(none)
60
2
36

Study Details

Study Description

Brief Summary

Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm.

Condition or Disease Intervention/Treatment Phase
  • Device: True circular microwave needle
N/A

Detailed Description

HCC is a serious threat to the health of people,Early treatment of HCC results in a good prognosis for patients. Microwave ablation (MWA) is an important method for the treatment of early HCC. The traditional MWA technology has a long diameter of the ablation foci which is much larger than the transverse diameter, so in order to obtain a sufficient transverse diameter, the long diameter is often too large beyond the tumor boundary. That will cause too much normal liver tissue is unnecessarily damaged, especially for patients with severe liver cirrhosis or patients with liver cirrhosis who have undergone liver resection. In addition, it is easy to cause damage to adjacent vital tissues and organs. Changes in tissue properties during ablation affect the stability of the microwave field, resulting in unpredictable ablation shapes, which may cause omissions during tumor ablation, especially in multiple overlapping ablation, resulting in incomplete ablation, or increasing the risk of local tumor progression after treatment. Microwave thermosphere ablation (MTA) technology is a new MWA technology. With the help of temperature control technology, field control technology and wave control technology, a single needle can produce predictable spherical ablation lesions. Theoretically, MTA can improve the controllability of the ablation foci, which is suitable for the purpose of conformal ablation of large tumors in clinical practice, thereby minimizing the damage of local thermal ablation to liver tissue and adjacent important organs. However, there are few reports on the comparison of the therapeutic effect of MTA and traditional MWA. This study intends to conduct a prospective randomized controlled study based on the two mature microwave treatment methods of MTA and traditional MWA ablation to explore the effectiveness and safety of MTA in clinical application, providing evidence-based medical evidence for the clinical application of MTA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Single-center, Prospective Randomized Controlled Study of Microwave Thermosphere Ablation and Traditional Microwave Ablation in the Treatment of Single Hepatocellular Carcinoma With a Diameter of ≤5cm
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: MTA Group

Use true circular microwave needle for ultrasound-guided thermal ablation in MTA (microwave thermosphere ablation) group.

Device: True circular microwave needle
Use true circular microwave needle for thermal ablation

No Intervention: MWA Group

Use normal microwave needle for ultrasound-guided thermal ablation in MTA (microwave ablation) group.

Outcome Measures

Primary Outcome Measures

  1. Comparison of progression-free survival between MTA and traditional MWA in HCC [6 to 12 months]

    Compare the time to tumor progression after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5 cm

Secondary Outcome Measures

  1. Comparison of the overall survival of MTA and traditional MWA in HCC [12 to 60 months]

    Compare the time to of all-cause mortality after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm

  2. Comparison of local progression rates of MTA and traditional MWA in HCC [6 to 12 months]

    Local progression was defined as new lesions with hyperenhancement in the arterial phase and low enhancement in the portal or delayed phase found adjacent to the ablation lesion (≤5 mm) during follow-up. Compare the local progression rates after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤ 5 cm

  3. Comparison of complete ablation rates of MTA and traditional MWA in HCC [1 month]

    Complete ablation was defined as the tumor showing no enhancement in three stages on contrast-enhanced imaging. Compare the rate of complete ablation after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5 cm

  4. Comparison of the complications rate of MTA and traditional MWA in HCC [immediately]

    Compare the rate of the complications during and after the therapy of MTA and traditional MWA in the treatment of patients with single hepatocellular carcinoma with a diameter of ≤5cm

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patient has high risk factors for HCC and was first diagnosed of HCC by by contrast-enhanced imaging (CECT/CEMRI/CEUS) and/or pathology ;

  2. Age range 18 to 75 years old;

  3. Single lesion with tumor diameter ≤5cm;

  4. Patient refuses surgery and determines to undergo microwave ablation

  5. Liver function Child Pugh A or B;

  6. No extrahepatic metastasis or portal invasion;

  7. Patient signs the informed consent.

Exclusion Criteria:
  1. The lesion has received treatment, including local ablation therapy and TACE therapy, etc;

  2. With portal vein invasion or extrahepatic metastases;

  3. Patient is with severe cardiopulmonary insufficiency.

  4. Patient is a pregnant or breastfeeding women.

  5. Patient is considered to be unsuitable to participate in the study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Tianjin Third Central Hospital

Investigators

  • Study Director: Xiang Jing, Tianjin Third Central Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tianjin Third Central Hospital
ClinicalTrials.gov Identifier:
NCT05361538
Other Study ID Numbers:
  • drjingxiang005
First Posted:
May 4, 2022
Last Update Posted:
May 4, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 4, 2022